Ollin Biosciences has reported compelling data from its Phase 1b “Jade” study, highlighting the superior performance of its bispecific antibody, OLN324, compared to the current market leader, faricimab. The trial evaluated patients suffering from diabetic macular edema (DME) and neovascular age-related macular degeneration (wAMD).
Significant clinical findings include:
-
Disease clearance: At the 12-week mark, nearly 90% of DME patients treated with a 4 mg dose of OLN324 achieved disease absence (central subfield thickness below 325 µm), significantly higher than the 57% observed in the faricimab group.
-
Anatomic and visual gains: The experimental therapy showed a 50% greater improvement in mean retinal drying for DME patients. Additionally, participants in both the DME and wAMD cohorts experienced numerically higher vision enhancements compared to those on the standard treatment.
-
Mechanism of action: OLN324 is characterized by its high potency for Ang2 and a smaller molecular size, which facilitates better tissue penetration following ocular injection.
-
Safety profile: No instances of intraocular inflammation or retinal vasculitis were reported among patients receiving the investigational drug during the study.
Following these results, the Texas-based biotech plans to initiate global Phase 3 trials for both indications within the current year. The company aims to position OLN324 as a potential primary standard of care in the global retinal therapeutics market, currently valued at approximately $15 billion.